Molecular Cancer Therapeutics
@MCT_AACR
The go-to journal for transitioning experimental therapies developed at the bench into clinical investigation, from preclinical study to phase I trials.
Histotripsy-Focused Ultrasound Treatment Abrogates Tumor Hypoxia Responses and Stimulates Antitumor Immune Responses in Melanoma brnw.ch/21wUu8w
Watch our interview with Analisa DiFeo, PhD, recipient of the 2025 Molecular Cancer Therapeutics Award for Outstanding Journal Article, to learn more about her research: brnw.ch/21wUtYK @DiFeoLab @umichmedicine @UMichPath @UMRogelCancer
New in Models and Technologies: CD24-Targeted CAR-T Cells Mediated Long-term Antitumor Efficacy through Activation of Endogenous Tumor Immune Responses brnw.ch/21wUqFN
Development of a Tumor-Specific Multivalent CD40 Agonist Antibody FAPxCD40 for Cancer Therapy: Balancing Efficacy and Toxicity brnw.ch/21wUoMc
New in Large Molecule Therapeutics: A Pharmacokinetic and Pharmacodynamic Model of an IL-12 Anchored-Drug Conjugate for the Treatment of Solid Tumors brnw.ch/21wUmWb
M4205 (IDRX-42) Is a Highly Selective and Potent Inhibitor of Relevant Oncogenic Driver and Resistance Variants of KIT in Cancer: brnw.ch/21wUl4E
5′-S-(3-Aminophenyl)-5′-thioadenosine, a Novel Chemoprotective Agent for Reducing Toxic Side Effects of Fluorouracil in Treatment of MTAP-Deficient Cancers: brnw.ch/21wUjhl
Read the developmental therapeutics article collection. brnw.ch/21wUhb7 #ESMOTATAsia25
Molecular Cancer Therapeutics is the central hub for #FirstDisclosures in cancer. Catch up on the latest articles: brnw.ch/21wUglf
Associate Editor @DanielleLarge2 is attending #ESMOTATAsia25. Reach out to her at [email protected] to schedule a meeting to discuss your ongoing research or to learn more about publishing at Molecular Cancer Therapeutics.
Coinhibition of Aurora Kinase B and SUV4-20H Induces Synthetic Lethality in Wild-type p53-Deficient Cancer Cells: brnw.ch/21wUfPW
Associate Editor @DanielleLarge2 will be attending #ESMOTATAsia25. Reach out to her at [email protected] to schedule a meeting to discuss your ongoing research or to learn more about publishing at Molecular Cancer Therapeutics.
Recently published in Small Molecule Therapeutics: Zidesamtinib Selective Targeting of Diverse ROS1 Drug-Resistant Mutations brnw.ch/21wUdRG
#OnlineFirst: TUB-040, a Homogenous and Hydrophilic NaPi2b-Targeting #ADC with Stably Linked #Exatecan, Exhibits Long-lasting Anti-tumor Activity and a Well-Tolerated Safety Profile. doi.org/10.1158/1535-7… #AntibodyDrugConjugate #FirstDisclosure #OpenAccess
Read "Towards Degrader-Antibody Conjugates," a collection focused on the preclinical to early clinical development of novel #ADCs and #proteindegraders: aacrjournals.org/collection/106…
Advances in Antibody–Drug Conjugates for Endometrial Cancer: brnw.ch/21wUagG
Stay up to date with all the latest issues of Molecular Cancer Therapeutics by receiving alerts directly to your inbox: brnw.ch/21wU8Ki
#FirstDisclosure A Novel B7-H4xCD3 Bispecific T-cell Engager (PF-07260437) Synergizes with Breast Cancer Standard of Care and Immune Checkpoint Therapies: brnw.ch/21wU4Xt
#OnlineFirst: DS-3939a: A TA-MUC1-directed #AntibodyDrugConjugate with Broad Anti-Tumor Activity. doi.org/10.1158/1535-7… #MUC1 #FirstDisclosure #OpenAccess
#FirstDisclosure PF-08046032: A Novel, Investigational CD25-Directed Antibody–Drug Conjugate Optimized for Selective Depletion of Regulatory T Cells in Advanced Malignant Tumors brnw.ch/21wU33q
